The treatment of ovarian cancer has historically been dominated by chemotherapy, but angiogenesis and PARP inhibitors are optimizing treatment options. The regulatory approvals of AstraZeneca /…
Clarivate Epidemiology's coverage of the COVID-19 vaccine comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…
With the increasing number of approved innovative, high-cost gene therapies, value assessment and novel approaches to reimbursement are rapidly gaining importance. To assist developers of gene…
NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…
NASH has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at risk of liver fibrosis,…
Triptans have long been the mainstay of acute treatment of migraine; however, in 2020, three novel oral nontriptan brands—Eli Lilly’s Reyvow, AbbVie / Allergan’s Ubrelvy, and Biohaven’s…
Several therapies from a range of drug classes are available to address the symptoms of narcolepsy; these symptoms include excessive daytime sleepiness (EDS) and cataplexy. Despite the availability…
Clarivate Epidemiology’s coverage of neuroblastoma comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…
Clarivate Epidemiology's coverage of scleroderma (systemic sclerosis) comprises epidemiological estimates of key patient populations across 14 mature and emerging pharmaceutical markets…
Clarivate Epidemiology's coverage of scleroderma (systemic sclerosis) comprises epidemiological estimates of key patient populations across 14 mature and emerging pharmaceutical markets…
According to Clarivate epidemiology, cognitive dysfunction (e.g., impaired attention / vigilance, memory, executive function) occurs in the vast majority of diagnosed schizophrenia patients and has…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Parkinson's disease patient populations covering 171 countries…
The systemic lupus erythematosus (SLE) therapy market in the United States is largely genericized and off-label. With the exception of GlaxoSmithKline’s Benlysta—which launched in 2011—the…
With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues…
Opioid addiction is a chronic disease, generally driven by a strong and irresistible urge or craving for the intake of opioid drugs and an inability to stop despite negative consequences to health…